Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to measure the effects of a chewable Simethicone tablet taken by mouth on middle-ear pressure in adults with a common cold and evidence of abnormal middle-ear pressure. In children and adults, middle-ear diseases such as otitis media (the buildup of fluid within the middle ear) and a form of temporary hearing loss occur if the Eustachian tube does not open, does not open often enough or is always open. Simethicone, available over-the-counter under several brand names including Gas-X, may help break up the bubbles that may block the opening of the Eustachian tube in the back of the nose during a cold, allowing air to pass between the nose and middle ear. This study requires a single visit to the Middle Ear Physiology Laboratory in the Oakland section of Pittsburgh. If eligible for the study, Eustachian tube function testing will be done; the Simethicone tablet or placebo (a tablet that looks and tastes like the Simethicone tablet but has no active ingredient) will be given and Eustachian tube function testing repeated.
For the Eustachian tube function testing, the subject and a technician are seated comfortably within a pressure chamber, a room-like chamber in which the air pressure can be varied much like in an airplane or submarine. Middle ear pressure will be measured in each ear by tympanometry, a test done by inserting a small probe (an earplug attached to a rubber or plastic tube that measures ear pressure) half-way into the ear canal and changing the pressure in the probe. Then, microphones will be placed in the ear canals and a sound source placed into one nostril. The chamber pressure is then decreased and increased to various pressures and middle ear pressure is measured at these various pressures.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| simethicone | Experimental | 125 mg tablet |
|
| placebo | Placebo Comparator | chewable calcium tablet |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Simethicone | Drug | single 125 mg chewable tablet |
| |
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Fraction of Middle Ear (ME) Pressure Equilibrated (FGE) | The proportion of the pressure chamber-ME pressure gradient equilibrated with 1 swallow | After achieving the desired ME-pressure chamber gradient at baseline and 30 min post treatment |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| William J Doyle, PhD | Department of Otolaryngology, Children's Hospital of Pittsburgh of UPMC | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Middle Ear Physiology Laboratory of Children's Hospital of PIttsburgh of UPMC | Pittsburgh | Pennsylvania | 15213 | United States |
Ninety subjects (31 males, 59 females)were screened; 25 subjects entered the randomization phase.
Recruitment began in March 2011 and was terminated in March 2013. Recruitment was done by advertisement in the community.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Simethicone | 125 mg tablet Simethicone: single 125 mg chewable tablet |
| FG001 | Placebo | chewable calcium tablet Placebo: chewable calcium tablet |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Analysis done by ears with evaluable tests.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Simethicone | 125 mg tablet Simethicone: single 125 mg chewable tablet |
| BG001 | Placebo | chewable calcium tablet Placebo: chewable calcium tablet |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Fraction of Middle Ear (ME) Pressure Equilibrated (FGE) | The proportion of the pressure chamber-ME pressure gradient equilibrated with 1 swallow | ears pre-treatment/ears post-treatment | Posted | Mean | Standard Deviation | ratio | After achieving the desired ME-pressure chamber gradient at baseline and 30 min post treatment | ears | Participants |
|
The subjects were assessed throughout the experimental procedure which lasted for 2 hours.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Simethicone | 125 mg tablet Simethicone: single 125 mg chewable tablet |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Ellen Mandel, MD | Middle Ear Physiology Laboratory | 412-692-6214 | mandele@pitt.edu |
Not provided
| ID | Term |
|---|---|
| D010033 | Otitis Media |
| D010031 | Otitis |
| ID | Term |
|---|---|
| D004427 | Ear Diseases |
| D010038 | Otorhinolaryngologic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D012841 | Simethicone |
| ID | Term |
|---|---|
| D004129 | Dimethylpolysiloxanes |
| D012828 | Silicones |
| D012833 | Siloxanes |
| D017646 | Organosilicon Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
chewable calcium tablet |
|
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Units | Counts |
|---|---|
| Participants |
|
| ears |
|
|
|
| 0 |
| 13 |
| 0 |
| 13 |
| EG001 | Placebo | chewable calcium tablet Placebo: chewable calcium tablet | 0 | 12 | 0 | 12 |
Not provided
Not provided
| D009930 |
| Organic Chemicals |
| D011108 | Polymers |
| D046911 | Macromolecular Substances |
| D001697 | Biomedical and Dental Materials |
| D008420 | Manufactured Materials |
| D013676 | Technology, Industry, and Agriculture |